

NEW ZEALAND KING SALMON INVESTMENTS LIMITED AND SUBSIDIARIES

FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2018

CONTENTS

FOR THE YEAR ENDED 30 JUNE 2018

		Page
Corpor	rate Information	Э
Consol	lidated statement of comprehensive Income	2
Consol	lidated statement of financial position	3
Consol	lidated statement of changes in equity	4
Consol	ilidated statement of cash flows	5
Notes t	to the consolidated financial statements	
1	Corporate information	6
2	Basis of preparation	6
3	Summary of significant accounting policies	7
4	New standards and interpretations not yet adopted	10
5	Segment Information	11
6	Other Income	11
7	Expenses	11
8	Financing Income and costs	12
9	Income tax	12
10	Components of other comprehensive income	13
11	Earnings per share	13
12	2 Cash and cash equivalents	13
13	3 Trade and other receivables	13
14	Inventories	14
15	5 Biological assets	14
16	Property, plant and equipment	15
17	7 Intangibles	16
18	Non-current assets held for sale	16
19	Interest bearing loans and borrowings	17
20	Trade and other payables	17
21	Employee benefits	17
22	2 Commitments and contingencies	17
23	Financial risk management	18
24	Fair values of financial instruments	20
25	5 Capital management	20
26	6 Capital and reserves	21
27	Events after balance date	21
28	Related party disclosures	22
29	Auditors remuneration	23
30	Reconciliation of the net cash flow from operating activities to profit/(loss)	23
	Comparison to prospective financial statements	23
Auditor	r'e Report	26

NEW ZEALAND KING SALMON INVESTMENTS LIMITED AND SUBSIDIARIES

CORPORATE INFORMATION

Board of Directors

Director

John William Dudley Ryder

Grantley Bruce Rosewame Mark Robert Hutton

Jack Lee Porus * Paul James Steere *

Thomas Chai Leng Song

Xin Wang *

Carol Yuen Ping Cheng

Nelson Yunshu Liu

Position Independent Non-Executive Chairman

Chief Executive Officer and Managing Director

Independent Non-Executive Director Non-Executive Director

Independent Non-Executive Director

Non-Executive Director Non-Executive Director

Non-Executive Director - Alternate to Wang Xin Non-Executive Director - Alternate to Wang Xin

6 June 2018 * These Directors retired by rotation and were re-appointed at the AGM held on 7 November 2017.

Appointment Date

1 September 2008

15 July 2016 23 September 2008

23 September 2008 23 September 2008

7 August 2008

23 February 2017 27 March 2018

Resigned 6 June 2018

Other Corporate Information

Bankers

The Bank of New Zealand

Deloitte Centre

Level 6, 80 Queen Street

Auckland

Auditors

Emst & Young (EY)

Christchurch

Level 4/93 Cambridge Terrace

New Zealand

Solicitors

Chapman Tripp Level 35

23 Albert Street Auckland New Zealand

Principal Place of Business

93 Beatty Street Annesbrook Nelson New Zealand

Registered Office

93 Beatty Street Annesbrook Nelson

New Zealand

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 30 JUNE 2018

		2018	2017
	Note	\$000	\$000
Revenue	5	160,271	136,351
Cost of goods sold	14	(145,320)	(119,879)
Fair value gain on biological transformation	15	50,309	54,845
Freight costs to market		(15,212)	(13,360)
Gross profit		50,048	57,957
Other income	6	1,822	2,574
Sales, marketing and advertising expenses		(10,381)	(8,748)
Distribution overheads		(3,348)	(2,993)
Corporate expenses	7	(6,728)	(7,261)
Other expenses	7	(2,931)	(2,996)
Earnings before interest, tax, depreciation and amortisation		28,482	38,533
Depreciation and amortisation expense	16, 17	(5,105)	(4,366)
Finance Income	8	198	188
Finance expenses	8	(888)	(1,990)
Profit before tax		22,687	32,365
Income tax expense	9	(6,562)	(9,601)
Net profit after tax		16,125	22,764
Other comprehensive income			
Foreign currency translation differences	10	120	12
Net movement on cash flow hedges	10	(2,571)	6,063
Income tax effect of movement on cash flow hedges	10	721	(1,700)
Share based payment expense	10	263	142
Net other comprehensive income/(loss that will subsequently reverse through profit or loss)		(1,467)	4,517
Total comprehensive income/(loss)		14,658	27,281
The state of the s			
Earnings per share	192		
Basic earnings per share	11	\$ 0.12 \$ 0.12	\$ 0.16
Diluted earnings per share	11	\$ 0.12	\$ 0.16

STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2018

		2018	2017
ASSETS	Note	\$000	\$000
Current assets			
Cash and cash equivalents	12	14,428	10,647
Trade and other receivables	13	12,426	11,688
Inventories	14	16,582	16,674
Biological assets	15	71,566	68,556
Non-current assets held for sale			421
Derivative financial assets	24	1,057	2,066
Total current assets	*	116,059	110,052
Non-current assets			
Property, plant and equipment	16	43,722	35,726
Biological assets	15	7,888	10,960
Derivative financial assets	24	1,884	3,196
Deferred tax asset	9	2,052	1,636
Intangible assets	17	5,114	3,687
Goodwill	17	39,255	39,255
Total non-current assets		99,915	94,460
TOTAL ASSETS		215,974	204,512
TOTAL ASSETS		210,374	204,312
LIABILITIES			
Current liabilities			
Frade and other payables	20	13,924	13,282
Employee benefits	21	3,384	3,028
Borrowings	19	461	414
Other financial liabilities	28	46	18
Derivative financial liabilities	24	1,189	1,277
Taxation payable		4,902	2,285
Total current liabilities		23,906	20,304
Non-current liabilities		All and a second of	11-41-41-41
Employee benefits	21	473	451
Borrowings	19	10,000	10,124
Deferred tax liabilities	9	13,995	14,010
Derivative financial liabilities	24	1,299	948
Total non-current liabilities	-	25,767	25,533
TOTAL LIABILITIES		49,673	45,837
NET ASSETS		166,301	158,675
	1.0		
EQUITY	512.200	792400 BANG	12022000000000
Share capital	26	122,579	122,518
Reserves		328	1,795
Retained earnings		43,394	34,362
TOTAL EQUITY		166,301	158,675
Net tangible assets per share			
Net tangible assets per share		\$ 1.22	\$ 1.15

alf of the Board, who authorised the issue of these financial statements on 28 August 2018

Elirector 28 August 2018

Director 28 August 2018

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 JUNE 2018

			Foreign Currency		Share Based		
		Share	Translation	Hedge	Payment	Retained	Total
		Capital	Reserve	Reserve	Reserve	Earnings	Equity
	Note	\$000	\$000	\$000	\$000	\$000	\$000
Balance as at 1 July 2017		122,518	(515)	2,168	142	34,362	158,675
Profit for the period		-	-	-	-	16,125	16,125
Other comprehensive income/(loss)	10	1.77	120	(1,850)	263	MANAGER S	(1,467)
Total comprehensive income/(loss) for the period		Strawall The Strawall	120	(1,850)	263	16,125	14,658
Shares issued	26	61		:-:		-	61
Distribution to shareholders	26	*	1,#0) - 5		(7,093)	(7,093)
Balance as at 30 June 2018	-	122,579	(395)	318	405	43,394	166,301
Balance as at 1 July 2016		25,296	(527)	(2,195)		14,440	37,014
Profit for the period		4	40	-		22,764	22,764
Other comprehensive income/(loss)	10	**	12	4,363	142		4,517
Total comprehensive Income/(loss) for the period	_	•	12	4,363	142	22,764	27,281
Increase in share capital in preparation for IPO	26	68,914			•	-	68,914
Shares issued	26	30,105	(40)	121	1/4	X(=):	30,105
Transaction costs arising on share issue	26	(1,797)	•			-	(1,797)
Distribution to shareholders	26		~	*	-	(2,842)	(2,842)
Balance as at 30 June 2017		122,518	(515)	2,168	142	34,362	158,675

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 30 JUNE 2018

	Note	2018 \$000	2017 \$000
5 H H H H H H H		34 Table 17	
Operating activities		161,212	125 162
Receipts from customers			135,163
Payments to suppliers		(97,453)	(97,428)
Payments to employees		(35,029)	(30,268)
Interest received		164	181
Interest paid		(597)	(1,317)
Insurance and settlement income		150	1,998
Income tax paid		(3,609)	(2,999)
Net cash flows from / (used in) operating activities	30	24,838	5,330
Investing activities			
Proceeds from sale of property, plant and equipment		19	29
Purchase of property, plant and equipment		(14,022)	(7,449)
Purchase of intangible assets		(88)	(48)
Net cash flow (used in) / from Investing activities		(14,091)	(7,468)
Financing activities			
Drawdown of revolving loan		124	(8,876)
Government grants received		148	110
Gross proceeds from share Issue		42	30,105
Transaction costs arising from share issue		7	(1,797)
Proceeds from shareholder advances			1,402
Repayment of shareholder advances		(89)	(7,651)
Payment of finance lease liabilities		(98)	(85)
Dividends paid		(7,093)	(2,842)
Net cash flows (used in) / from financing activities	ž.	(6,966)	10,366
Net increase/(decrease) in cash and cash equivalents		3,781	8,228
Cash and cash equivalents at 1 July	12	10,647	2,419
Cash and cash equivalents at 30 June	12	14,428	10,647

FOR THE YEAR ENDED 30 JUNE 2018

1. CORPORATE INFORMATION

The financial statements of New Zealand King Salmon Investments Limited (the Company) and its subsidiaries (together the Group) for the year ended 30 June 2018 were authorised by the directors on 28 August 2018.

New Zealand King Salmon Investments Limited is a profit-orientated company incorporated and domiciled in New Zealand. The Company is registered under the Companies Act 1993 and listed on the NZX Main Board ("NZX") and the Australian Securities Exchange ("ASX"). The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013.

The Group is principally engaged in the farming, processing and sale of premium salmon products.

2. BASIS OF PREPARATION

a. Statement of compliance

The consolidated financial statements comply with International Financial Reporting Standards (IFRS) and also with New Zealand Equivalents to International Financial Reporting Standards (NZ IFRS).

b. Basis of measurement

The financial statements have been prepared on a historical cost basis except for biological assets and financial instruments which have been measured at fair value.

c. Significant accounting judgements, estimates and assumptions

The preparation of the Group's consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported outcomes of revenues, expenses, assets, liabilities and the accompanying disclosures. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Uncertainties about these assumptions and estimates could result in an outcome that requires a material adjustment to the carrying amount of assets or liabilities in future periods.

Specific areas requiring significant estimates and judgements include:

Valuation of biological assets

The Group recognises stocks of live fish at fair value less costs to sell according to the principles of NZ IAS 41 Agriculture. The fair value is measured using a valuation model that relies on various assumptions and information available at balance date, Inputs include anticipated market prices, quality mix, current weights of livestock relative to expected harvest weight, mortality rates, growth rates and production costs. The income or loss that is ultimately recognised at time of sale may be significantly different from that implied by the fair value adjustment at the end of a reporting period. The fair value uplift from accumulated costs to date has no cash impact. Further details of the valuation and sensitivity to change in key inputs are given in note 15.

Impairment testing of intangibles

The Group reviews the carrying value of goodwill on an annual basis and assesses whether it is impaired according to the principles of NZ IAS 36 Impairment of Assets. This requires the goodwill to be allocated to cash generating units with which it would naturally be associated and the value in use of the cash generating units to be estimated. The value in use is estimated using a standard industry model that relies on various assumptions and information available at balance date. Inputs include estimations of the growth rate of the Group, future market conditions, prices, and discount rates. Further details of the value in use assessment are given in note 17.

Valuation of financial derivatives

The Group recognises financial derivatives at fair value according to the principles of NZ IFRS 13 Fair Value Measurement. The value is calculated by a third party expert using an industry standard model. Inputs to the model are obtained externally by the service provider. Further details of the valuation are included in note 24.

Useful lives of assets

The Group estimates the useful lives of property, plant and equipment and intangible assets based on historical performance and currently consented future asset uses.

d. Foreign currency translation

Functional and presentation currency

The Group's consolidated financial statements are presented in New Zealand dollars, which is also the parent Company's functional currency. The Australian subsidiary's functional currency is Australian dollars which is translated into the presentation currency in these financial statements. The USA subsidiary's functional currency is United States dollars which is translated into the presentation currency in these financial statements.

Transactions and balances

Transactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange at balance date.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined.

Translation of Group subsidiaries functional currency to presentation currency

The assets and liabilities of both the Australian and USA subsidiaries are translated into New Zealand dollars at the rate of exchange at balance date. Revenues and expenses are translated at rates approximating the exchange rate at the date of the transaction. The exchange differences arising on translation for consolidation are recognised in other comprehensive income.

FOR THE YEAR ENDED 30 JUNE 2018

3. SUMMARY OF SIGNIFICIANT ACCOUNTING POLICIES

a. Basis of consolidation

The financial statements comprise the financial statements of New Zealand King Salmon Investments Limited and its subsidiaries (per note 28) as at 30 June each year. Subsidiaries are all those entities over which the Company has control.

The financial statements of the subsidiaries are prepared for the same reporting period as the Parent company using consistent accounting policies.

In preparing the consolidated financial statements, all intercompany balances and transactions, income and expenses and profit and losses resulting from intra-group transactions have been eliminated in full.

Subsidiaries are fully consolidated from the date on which control is obtained by the Group and cease to be consolidated from the date on which control is transferred out of the Group.

b. Business combinations

Business combinations are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value which is calculated as the sum of the acquisition date fair value of assets acquired by the Group and the liabilities assumed by the Group. Acquisition related costs are expensed as incurred and included in administrative expenses. Any contingent consideration to be transferred by the Group is recognised at fair value at acquisition date.

c. Financial instruments

All financial instruments are initially recognised at the fair value of the consideration received, less directly attributable transaction costs in the case of financial assets and liabilities not recorded at fair value through profit or loss. Subsequently the Group applies the following accounting policies for financial instruments:

Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at bank and call deposits. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits net of outstanding bank overdrafts.

Trade and other receivables

Short term trade and other receivables are not discounted and are initially stated at cost. Gains and losses are recognised in the profit or loss when the receivables are derecognised or impaired.

Loans

Loans and amounts owing from related companies are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial recognition such assets are carried at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the loans are derecognised or impaired.

Trade and other payables

Trade and other payables are carried at cost due to their short term nature and are not discounted. They represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. The amounts are unsecured and are usually paid within 30-60 days of recognition.

Interest bearing borrowings

After initial recognition interest bearing borrowings are subsequently measured at amortised cost using the effective interest method. Fees paid on establishment of loan facilities that are yield related are included as part of the carrying amount. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance date. Borrowing costs are generally recognised as an expense when incurred with the exception of borrowing costs associated with a qualifying asset which are capitalised as part of the cost of that asset.

Financial guarantee

Financial guarantee contracts issued by the Group are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial Guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributed to the issuance of the guarantee. Subsequently the liability is measured at the higher of the best estimate of the expenditure required to settle the present obligation at balance date and the amount recognised less cumulative amortisation.

Derivative financial instruments and hedging

The Group uses derivative financial instruments including forward currency contracts, options and interest rate swaps to hedge risks associated with interest rate and foreign currency fluctuations. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured to fair value at balance date. Derivatives are carried as assets when their fair value is positive and as liabilities when their fair value is

The fair values of forward currency contracts are calculated by reference to current forward exchange rates for contracts with similar maturity profiles. The fair values of interest rate swaps are determined by reference to market values for similar instruments.

The Group designates its derivative financial instruments as hedges of a particular risk essociated with a recognised asset or liability or a highly probable commitment that could affect profit or loss. The effective portion of the gain or loss on the hedging instrument is recognised directly in other comprehensive income in the hedge reserve, while the ineffective portion is recognised in profit or loss as other income or expenses.

Amounts accumulated in equity are transferred to profit or loss when the hedged item affects profit or loss.

d. Inventories

Inventories including raw materials, work in progress and finished goods are valued at the lower of cost or net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

Raw materials — the cost of fish is measured at fair value at harvest date. The cost of other raw materials is based on the purchase price including import duties and other taxes, transport, handling and other costs directly attributable to the acquisition of the goods and materials. Costs are determined on a weighted average basis.

Manufactured finished goods and work in progress - cost of direct materials, labour and a proportion of manufacturing overheads appropriate to the state of manufacture. Costs are assigned on the basis of weighted average costs. The cost of items transferred from biological assets is their fair value less costs to sell at the

Net realisable value - the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale.

FOR THE YEAR ENDED 30 JUNE 2018

e. Biological assets

Biological assets include fish livestock measured at fair value less estimated costs to sell. The net gain or loss resulting from the fair value measurement is recognised in profit or loss.

The fair value of fish livestock is derived from the amount expected to be received from the sale of the asset in an active market. The target live weight of the harvestable fish is defined as a fish with a live weight of 4kg or greater. Many fish are harvested with a live weight above or below this weight.

For brood stock and fish where little biological transformation has taken place since initial cost was incurred, cost less impairment is used as an approximation of fair value. This value is used up to the point at which fish are transferred to sea water. Fish stock is transferred to inventory at the time of harvest. The transfer is recorded at its fair value which is deemed to be cost for the purposes of inventory valuation.

f. Property, plant and equipment

Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Depreciation is provided on a straight line basis over the estimated useful lives of the assets as follows:

Freehold land not depreciated
Freehold buildings twenty to fifty years
Building fit out three to twenty five years
Leasehold improvements five to ten years
Plant, furniture and fittings three to twenty years

Motor vehicles five years
Sea vessels ten to twenty years

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively if appropriate. An asset's carrying value is written down immediately to its recoverable amount if its carrying value is greater than its estimated recoverable amount.

An item of property, plant and equipment is derecognised upon disposal or when no further future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in profit or loss in the year the asset is derecognised.

g. Leases

The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset.

Group as a lessee

A lease is classified at the inception date as a finance lease or an operating lease. Finance leases, which transfer to the Group substantially all the risks and benefits incidental to ownership of the leased item, are capitalised at the inception of the lease at the fair value of the leased asset or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between the finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised as an expense in profit or loss.

Capitalised leased assets are depreciated over the shorter of the estimated useful life of the asset and the lease term if there is no reasonable certainty that the Group will obtain ownership by the end of the lease term.

Operating lease payments are recognised as an expense in profit or loss on a straight-line basis over the lease term. Lease incentives are recognised in profit or loss as an integral part of the total lease expense.

h. Intangibles

Intangible assets acquired separately or in a business combination are initially measured at cost. The cost of an intangible asset acquired in a business combination is its fair value as at the date of acquisition. Following initial recognition intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. Internally generated intangible assets are not capitalised and the expenditure is recognised in profit or loss in the year in which the expenditure is incurred.

The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortised over the useful life and tested for impairment whenever there is an Indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for prospectively by changing the amortisation period or method, as appropriate, which is a change in accounting estimate. The amortisation expense on intangible assets with finite lives is recognised in profit or loss in the expense category consistent with the function of the intangible asset.

Intangible assets with indefinite useful lives are not amortised but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of useful life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to definite is made on a prospective basis.

A summary of the policies applied to the Group's intangible assets is as follows:

Goodwill and trade marks

Useful lives: Indefinite Internally generated or acquired: Acquired

Intellectual property, marine farm and hatchery licences and marina berth

Useful lives: Fin

Amortisation method used: Straight line, five to thirty five years

Internally generated or acquired:

Computer Software

92.79

Useful lives:

Finite

Acquired

Amortisation method used: Internally generated or acquired: Straight line, four to seven years

internally generated or acquired:

Acquired

FOR THE YEAR ENDED 30 JUNE 2018

i. Research and development costs

Research costs are generally expensed as incurred. Development expenditures are capitalised as intangible assets when the Group can demonstrate:

- Costs can be reliably measured.
- Completion of the project is technically feasible.
- Resources are available to complete the project.
- There is an intention to use the resulting asset and it will generate future economic benefits.
- During the period of development the asset is tested for impairment annually.

Employee benefits

Wages, salaries, annual leave and sick leave

Liabilities for wages and salaries including non-monetary benefits, annual leave and accumulating sick leave expected to be settled within 12 months of the reporting date are recognised in respect of employees' services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled. Liabilities for non-accumulating sick leave are recognised when the leave is taken and are measured at the rates paid or payable.

Long service leave

The liability for long service leave is recognised and measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service.

Defined contribution plans

Contributions made to a defined contribution plan are expensed as incurred.

k. Contributed equity

Ordinary shares

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction net of tax from the proceeds. Other capital raising costs are expensed as incurred.

I. Revenue Recognition

Revenue is recognised and measured at the fair value of the consideration received or receivable to the extent it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Sale of goods

Revenue is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Risks and rewards of ownership are passed to the buyer depending on the agreed shipping terms. This is typically when legal ownership is passed over.

Interest income

Revenue is recognised as interest accrues using the effective interest method.

Insurance proceeds

Insurance proceeds are recognised in the financial statements when receipt is virtually certain and can be measured reliably.

m. Taxes

Income taxes

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the current period's taxable income. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the balance sheet

Deferred income tax is provided on all temporary differences at the balance sheet date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

The carrying amount of deferred income tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised. Unrecognised deferred income tax assets are reassessed at each balance sheet date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date.

Income taxes relating to items recognised directly in equity are recognised in equity and not in profit or loss.

Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to the same taxable entity and the same taxation authority.

Other taxes

Revenues, expenses and assets are recognised net of the amount of GST, except when:

- The GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable.
- Receivables and payables, which are stated with the amount of GST included.
- The net amount of GST recoverable from or payable to the taxation authority is included as part of receivables or payables in the balance sheet.
- Commitments and contingencies are disclosed net of the amount of GST recoverable from or payable to the taxation authority.
- The Group recognises uncertain tax positions as a liability where it is probable that an outflow of resources will be required.

FOR THE YEAR ENDED 30 JUNE 2018

n. Share-based payments

Certain employees of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (equity-settled transactions). The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model, further details of which are given in Note 26.

That cost is recognised in employee benefits expense, together with a corresponding increase in equity (other capital reserves), over the period in which the service and, where applicable, the performance conditions are fulfilled (the vesting period). The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of comprehensive income for the period represents the movement in cumulative expense recognised as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

No expense is recognised for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. Where awards include a market or non-vesting condition, the transactions are treated as vested irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

When the terms of an equity-settled award are modified, the minimum expense recognised is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense, measured as at the date of modification, is recognised for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee. Where an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss.

4. NEW STANDARDS AND INTERPRETATIONS NOT YET ADOPTED

Various new standards, amendments to standards and interpretations are effective for annual periods beginning on or after the current reporting period and have not been applied in preparing these consolidated financial statements. The following changes may have a significant effect on the consolidated financial statements of the group:

NZ IFRS 9: Financial Instruments

NZ IFRS 9, 'Financial Instruments' replaces NZ IAS 39 'Financial Instruments: Recognition and Measurement'. The standard is effective for annual periods beginning on or after 1 January 2018 and earlier application is permitted.

The new standard addresses the classification, measurement and de-recognition of financial assets and financial liabilities, introduces new rules for hedge accounting and introduced a new impairment model.

The Group intends to adopt NZ IFRS 9 on its effective date and is currently assessing its full impact. The standard is not expected to significantly impact the Group as the valuation and measurement of the Group's financial assets and liabilities are not expected to change.

NZ IFRS 15: Revenue from Contracts with Customers

NZ IFRS 15, 'Revenue from Contracts with Customers' establishes the framework for revenue recognition. The standard replaces NZ IAS 18 'Revenue' and NZ IAS 11 'Construction Contracts' and related interpretations. The standard is effective for annual periods beginning on or after 1 January 2018 and earlier application is permitted.

The new standard is based on the principle that revenue is recognised when control of a good or service transfers to a customer. The notion of control replaces the existing notion of risks and rewards.

The Group intends to adopt NZ IFRS 15 on its effective date and is currently assessing its full impact. This standard is not expected to significantly impact the Group as the majority of sales enable control to be transferred to customers within one to two days of dispatch.

NZ IFRS 16: Leases

NZ IFRS 16, 'Leases', replaces the current guidance in NZ IAS 17. Under NZ IFRS 16, a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Under NZ IAS 17, a lessee was required to make a distinction between a finance lease (on balance sheet) and an operating lease (off balance sheet). NZ IFRS 16 now requires a lessee to recognise a lease liability reflecting future lease payments and a 'right-of-use asset' for virtually all lease contracts.

The standard is effective for accounting periods beginning on or after 1 January 2019. Early adoption is permitted but only in conjunction with NZ IFRS 15, 'Revenue from Contracts with Customers'.

The Group intends to adopt NZ IFRS 16 on its effective date and has yet to assess its full impact. The group currently leases a number of offices, buildings, vehicles, water space and minor plant and equipment.

FOR THE YEAR ENDED 30 JUNE 2018

5. SEGMENT INFORMATION

Segment results

For management purposes, the Group is organised into three business units based on geographical sales market and customer channel. The operating results of the business units are monitored for the purpose of making decisions about resource allocation and performance assessment.

The Group's reportable segments are:

New Zealand Retail

The company provides these customers with pre-packed value added products (including wood roasted and cold smoked product), whole fresh fish and pre-cut fillets.

New Zealand Foodservice

The company provides these customers with a broad variety of salmon products including whole fresh fish, pre-cut fillets, portions and a range of smoked products. Export

Predominantly customers based outside New Zealand most of whom currently fall into the Foodservice category as described above.

Segment performance is evaluated at the EBITDA level and results are as follows:

	New Zealand Retail	New Zealand Foodservice	Export Market	Total
	\$000	\$000	\$000	\$000
Year ended 30 June 2018				
Revenue	41,415	37,811	81,045	160,271
Segment EBITDA	4,904	6,702	16,876	28,482
Year ended 30 June 2017				
Revenue	35,439	38,385	62,527	136,351
Segment EBITDA	7,031	12,101	19,401	38,533
Depreciation, amortisation, finance income and costs, and fair value gains and losses	on financial assets a	re not allocated to in	dividual segments as the	underlying

Depreciation, amortisation, finance income and costs, and fair value gains and losses on financial assets are not allocated to individual segments as the underlying instruments are managed on a group basis.

Segment profit reconciles to profit before income tax as follows:	2018	2017
	\$000	\$000
Segment profit	28,482	38,533
Depreciation, amortisation and impairment	(5,105)	(4,366)
Net finance costs	(690)	(1,802)
Group profit before tax	22,687	32,365

The Group does not prepare information allocating assets and liabilities to the market facing segments as all material assets and liabilities are managed on a group basis.

		2018	2017
Revenue by geographical location of customers		\$000	\$000
New Zealand		79,226	73,824
North America		48,435	35,956
Australia		11,497	12,035
Japan	W:	8,265	6,034
Europe		2,860	1,986
Other		9,988_	6,516
Total revenue		160,271	136,351

Sales net of settlement discounts to two major customers for the year totalled \$16,595k and \$16,535k or 10.4% and 10.3% respectively (2017 one major customer accounted for \$16,511k or 13.1%). In both years, these customers were lockyded to the New Zeeland Robbit seement.

6. OTHER INCOME	2018	2017
Other income	\$000	\$000
Grants received	148	112
[2] 전 전 전 전 전 전 전 전 전 전 전 전 전 전 전 전 전 전 전	140	
Supplier settlement	4400	1,784
Rebate on supply	1,135	
Insurance settlements	188	214
Supplier forgiveness of debt	<u></u>	348
Contract penalties (received)	175	
Profit on sale of property, plant and equipment	19	28
Other Income	157	88
Total other income	1,622	2,574
7. EXPENSES	2018	2017
Corporate and other expenses include:	\$000	\$000
Trade receivables written off	10	1
Impairment of trade receivables	20	84
Professional fees related to capital raising		1,970
Research cost	660	849
Water space process expense	171	846
Loss on Assets Held for Sale	113	180
Minimum lease payments - operating leases	1,477	1,118
Directors' fees	420	320
Other directors' expenses	43	18
Donations	17	43
	2018	2017
Employee benefits expense	\$000	\$000
Wages and salaries	29,616	26,445
Defined contribution plan expenses	683	569
Restructuring costs	40	(4)
Other employee benefits expenses	3,933	3,476
Outsourced labour	1,399	555
Total employee benefits expense	35,671	31,041

FOR THE YEAR ENDED 30 JUNE 2018

8. FINANCE INCOME AND COSTS	2018	2017
Finance income	\$000	\$000
Interest income	198	188
Total finance income	198	188
FRS	2018	2017
Finance costs	\$000	\$000
Bank facility fees	293	284
Interest on bank loans and overdrafts	595	1,210
Interest on shareholder loans	19 <u>4</u>	496
Total finance costs	868	1,990
9. INCOME TAX	2018	2017
Recognised in the consolidated statement of comprehensive income	\$000	\$000
Current Income tax expense	6,143	4,745
Under provision - previous year	127	(49)
Deferred tax relating to origination and reversal of temporary differences	292	4,905
Total income tax expense/(credit) in the statement of comprehensive income	6,562	9,601
Total moonio tax expenses (creaty in the statement of complementary moonie	0,002	3,001
Tax amounts posted directly to equity	(721)	1,700
Reconciliation of tax expense to statutory income tax rate Profit/(loss) before tax	22,687	32,365
The state of the s		
Income tax using the company tax rate 28%	6,352	9,063
Non deductible/non assessable items	73	617
Under provision - previous year	127	(49)
Prior period adjustment	(30)	
Other differences	40	(30)
Total tax expense	6,562	9,601
Statement of financial position deferred tax assets and liabilities	2018	2017
Deferred tax liabilities	\$000	\$000
Accelerated depreciation for tax purposes	(2,807)	(2,853)
Fair value adjustment to biological assets	(10,300)	(9,640)
Gains on foreign currency hedges	(426)	(1,108)
Increase accounting cost for finished goods	(462)	(409)
Total deferred tax liabilities	(13,995)	(14,010)
Deferred tax assets		
Provision for doubtful trade debtors	23	43
Provision for employee benefits	793	570
Impairment of non-current assets		176
Share based payments	113	40
Losses on foreign currency hedges	299	258
Other provisions	824	549
Total deferred tax assets	2,052	1,636
Not deferred tax liability	(11,943)	(12,374)
Statement of comprehensive income deferred tax assets and liabilities	2018	2017
Deferred tax liabilities	\$000	\$000
Accelerated depreciation for tax purposes	(42)	129
Fair value adjustment to biological assets	661	4,991
Increase accounting cost for finished goods	53	38
Total deferred tax ilabilities	672	5,158
Deferred tax assets		
Provision for doubtful trade debtors	20	(26)
Provision for employee benefits	(222)	(24)
Impairment of non-current assets	176	114
Share based payments .	(74)	(40)
Other provisions	(280)	(277)
Total deferred tax assets	(380)	(253)
		4,905

Imputation credit account
The Imputation credit account balance in the New Zealand King Salmon Company Limited as at 30 June 2018 is \$3,504k (2017: \$1,821k).

FOR THE YEAR ENDED 30 JUNE 2018

10. COMPONENTS OF OTHER COMPREHENSIVE INCOME	2018	2017
Movement in reserves	\$000	\$000
Forward currency contracts	State of the state	130
Reclassification during the year to profit or loss	12	(18)
Income tax effect	(2)	5
Realised/unrealised net gain/(loss) during the year	(2,436)	4,997
Income tax effect	682	(1,400)
Interest rate swaps		22/W07/19/24/E
Realised/unrealised net gain/(loss) during the year	(147)	1,084
Income tax effect	41	(305)
Currency translation differences		12517.7551
Currency translation differences	120	12
Share based payment expenses		
Share based payment expense	263	142
Not movement in reserves	(1,467)	4,517

11. EARNINGS PER SHARE

Basic earnings per share amounts are calculated by dividing the profit for the year attributable to shareholders of the Company by the weighted average number of ordinary shares on issue during the year. Diluted earnings per share assume conversion of all potential ordinary shares in determining the weighted average number of ordinary shares on issue.

Earnings per share	2018 \$000	2017 \$000
Profit attributable to ordinary equity holders	16,125	22,764
8 8	# of Shares	# of Shares
	000	000
Weighted average number of ordinary shares for diluted earnings per share	138,397	138,158
Basic earnings per share	\$0.12	\$0.16
Diluted earnings per share	\$0.12	\$0.16
12. CASH AND CASH EQUIVALENTS	2018	2017
Cash and cash equivalents	\$000	\$000
Cash at bank and on hand	14,021	10,175
Short-term deposits	407	472
Total cash and cash equivalents	14,428	10,647
13. TRADE AND OTHER RECEIVABLES	2018	2017
Trade and other receivables	\$000	\$000
Trade receivables	11,016	10,848
Allowance for Impairment loss	(110)	(153)
Prepayments	1,103	970
Other receivables	417	23
Total trade and other receivables	12,426	11,688

Trade receivables generally have 20-30 day terms and are recognised at their realisable value. Collectability of trade receivables is reviewed on an ongoing basis. Debts that are known to be uncollectable are written off when identified. Impairment losses are recognised net of insurance proceeds when there is objective evidence that the Group will not be able to collect the debt.

	2010	2017
Ageing analysis of trade receivables	\$000	\$000
> 90 days overdue	112	90
31 - 90 days overdue	141	68
15 - 30 days overdue	784	49
< 15 days overdue	356	1,867
Not yet due	9,623	8,774
Total receivables	11,016	10,848
	2018	2017
Receivables impairment movement	\$000	\$000
As at 1 July	153	69
Additional provisions for impairment	130	151
Receivables written off during the year	(10)	1
Reversal of unused amounts	(163)	(68)
As at 30 June	110	153

2017

FOR THE YEAR ENDED 30 JUNE 2018

14. INVENTORIES	2018	2017
Inventories	\$000	\$000
Raw materials	9,822	9,525
Work in progress	106	-
Finished goods	6,654	7,149
Total Inventories	16,582	16,674
The closing cost of finished goods as at 30 June 2018 includes a fair value uplift at point of harvest of \$2.354k (2017: \$2.3	To the second se	William Franklin
The closing cost of finished goods as at 30 June 2018 includes a fair value uplift at point of harvest of \$2,354k (2017: \$2,3 (2017: \$1,446k).	To the second se	William Franklin
The closing cost of finished goods as at 30 June 2018 includes a fair value uplift at point of harvest of \$2,354k (2017: \$2,3 (2017: \$1,446k).	To the second se	sion of \$1,638k
(2017: \$1,446k).	391k) and an impairment provi	William Franklin
	391k) and an impairment provi	sion of \$1,638k
(2017: \$1,446k). Amount of inventories recognised as an expense in the statement of comprehensive income	391k) and an impairment provi	sion of \$1,638k 2017 \$000

The cost of inventories recognised as an expense for the year ended 30 June 2018 includes a fair value uplift at point of harvest of \$47,988k (2017: \$37,135k).

15. BIOLOGICAL ASSETS

The Group has three hatcheries in the South Island and eight operational marine salmon farms in the Mariborough Sounds. The fish livestock typically grow for up to 31 months before harvest.

Biological assets	Cost \$000	Fair Value Gain \$000	Total \$000
As at 1 July 2017	45,087	34,429	79,516
Increase due to biological transformation 1	67,846	36,692	104,538
Decrease due to harvest 2	(57,768)	(47,951)	(105,719)
Decrease due to mortality 3	(12,498)		(12,498)
Changes in fair value 4	Daniel Branch	13,617	13,617
As at 30 June 2018	42,667	36,787	79,454

¹ Biological transformation fair value is impacted by volume increases and fish weight at reporting date relative to the target fish harvest weight of 4 kgs (proportional recognition).

A Changes in fair value are impacted by movements in margin primarily being changes in sales price and costs to sell (fish cost, harvest, processing and freight to market).

Biological assets Cost \$000	Fair Value Gain \$000	Total \$000
As at 1 July 2016 36,347	16,603	52,950
Increase due to biological transformation 70,330	50,606	120,936
Decrease due to harvest (56,346)	(37,019)	(93,365)
Decrease due to mortality (5,244)		(5,244)
Changes in fair value	4,239	4,239
As at 30 June 2017 45,087	34,429	79,516
	2018	2017
Fair value gain/(loss) recognised in profit and loss	\$000	\$000
Gain arising from growth of biological assets	36,692	50,606
Movement in fair value of biological assets	13,617	4,239
Total fair value gain on biological transformation	50,309	54,845
	2018	2017
Harvested blomass	mt	mt
Harvested live weight biomass	9,112	8,218
Total live weight harvested for the period (metric tonne)	9,112	8,218
	2018	2017
Estimated closing biomass	mt	mt
Closing fresh water stocks	105	142
Closing sea water stocks	5,286	6,085
Total estimated closing biomass live weight as at period end	5,391	6,227

² Harvested fair value is included in cost of goods sold in the statement of comprehensive income and is calculated by multiplying the current years harvest (biomass) by the prior years estimated gross margin per kg (recognised at 100%).

³ Mortality cost is expensed directly to the statement of comprehensive income in the period which it occurs and is not subject to a fair value uplift.

FOR THE YEAR ENDED 30 JUNE 2018

Fair value measurement

Measurement of fair value is performed using a fair value model. The method of valuation therefore fails into level 3 of the fair value hierarchy as the inputs are unobservable inputs.

The valuation of biological assets is carried out separately for each site at a brood and strategy level. Estimated actual cost up to the date of harvest per site is used to measure the expected margin at the time the fish is defined as ready for harvest, being 4.0kg live weight. Selling price is estimated at balance date based on the most relevant future market price at expected harvest date. The expected gross margin is recognised proportionately based on average blomass at reporting date. Fair value measurement commences at the date of transfer to sea water as this is considered the point at which the fish commence their grow out cycle.

Fair value risk and sensitivity

16. PROPERTY, PLANT AND EQUIPMENT

The Group is exposed to financial risks relating to the production of salmon stocks including climatic events, disease and contamination of water space.

The Group seeks to produce and market the highest quality salmon products. Extensive monitoring and benchmarking is carried out to provide optimum conditions and diets to maximise fish performance during the grow out cycle. Sales are maintained in a range of brands, products and markets to maximise returns from the quality mix of fish harvested. The Group has insurance to cover some of the risks relating to the livestock.

The estimate of unrealised fair value gain from cost is based on several assumptions. Changes in these assumptions will impact the fair value calculation. The realised profit which is achieved on the sale of inventory will differ from the calculations of fair value of biological assets because of changes in key factors such as the final market destinations of inventory sold, changes in price, foreign exchange rates, harvest weight, growth rates, mortality, cost levels and differences in harvested fish quality.

Leaving all other variables constant a 10.0% increase/decrease in average future sales prices would increase/decrease the fair value of biological assets on hand and profit before tax by \$10.8m (2017: 5% increase/decrease \$5.4m) (excludes the impact of finished goods), while a 10.0% increase/decrease in future harvest volume would increase/decrease the fair value of biological assets on hand and profit before tax by \$3.6m (2017: 5% increase/decrease \$1.7m).

A 10% increase/decrease in costs to sell would decrease/increase the fair value of biological assets on hand and profit before tax by \$7.0m (2017: 5% increase/decrease \$3.5m). Changes in fish health and environmental factors may affect the quality of harvested fish, which may be reflected in realised profit via both achieved sales price and production costs.

Plant

24,059

30.046

2,934 4.734

886

	Freehold land and buildings	equipment and fittings	Vehicles and sea vessels	Construction in progress	Total
Cost	\$000	\$000	\$000	\$000	\$000
As at 1 July 2017	9,029	50,919	2,385	1,085	63,418
Additions	715	4,744	137	7,573	13,169
Disposals	(49)	(4,456)	(157)	(5,724)	(10,386)
As at 30 June 2017	9,695	51,207	2,365	2,934	66,201
Additions	301	10,427	334	12,009	23,071
Disposals		(116)	(97)	(10,209)	(10,422)
As at 30 June 2018	9,996	61,518	2,602	4,734	78,850
Depreciation and Impairment					
As at 1 July 2017	1,442	27,685	1,694	¥	30,821
Depreciation	250	3,748	125	<u> </u>	4,123
Impairment				<u> </u>	5. - 5
Disposals	(33)	(4,285)	(151)		(4,469)
As at 30 June 2017	1,659	27,148	1,668	The same of the sa	30,475
Depreciation	281	4,437	145		4,863
Impairment	3.77	0.5 W 2		-	-
Disposals		(113)	(97)	*	(210)
As at 30 June 2018	1,940	31,472	1,716	100000000 - 1100 - 1200	35,128

Borrowing costs

Net Book Value As at 30 June 2017 As at 30 June 2018

There were no borrowing costs capitalised in 2018 (2017: \$nil).

Impairment

There were no impairment losses recognised in 2018 (2017; \$nil).

Finance Leases

The carrying value of property, plant and equipment held under finance leases as at 30 June 2018 was \$310k (2017: \$353k). There were no additions of property, plant and equipment under finance leases in the 2018 year, \$nii (2017: \$136k). Leased assets are pledged as security for the related finance lease liabilities.

8,036

8.056

FOR THE YEAR ENDED 30 JUNE 2018

INTANGIBLES	Development in progress	Trademarks	Farm and hatchery licenses	Software	Goodwill	Total
Cost	\$000	\$000	\$000	\$000	\$000	\$000
As at 1 July 2016	3	242	4,322	3,927	39,255	47,749
Additions	457	MO297241	57	11	1.252.0.252.0	525
Disposals	(452)	12 12 12 12 12 12 12 12 12 12 12 12 12 1	194	(1,817)	4	(2,269)
Transferred to assets held for sale	M-7, 5	14		1 8147315 8	-	15177777
As at 30 June 2017	8	242	4,379	2,121	39,255	46,005
Additions	1,363		6	524	-	1,893
Disposals	(541)			0.72	*	(541)
Transferred from assets held for sale	M A		308	9₩3		308
As at 30 June 2018	830	242	4,693	2,645	39,255	47,665
Depreciation and impairment						
As at 1 July 2016		200	680	3,743	9	4,623
Amortisation			131	112		243
Disposals	-	를 보고 있다. 		(1,812)	<u> </u>	(1,812)
Impairment	- D		<u> </u>	Water		
As at 30 June 2017		200	811	2,043		3,054
Amortisation			141	101	-	242
Disposals	-		127.75			1
Impairment	24	4	-	34	-	-
As at 30 June 2018		200	952	2,144		3,296
Net Book Value						
As at 30 June 2017	. 8	42	3,568	78	39,255	42,951
As at 30 June 2018	830	42	3,741	501	39,255	44,369

Goodwill

Goodwill resulted from the acquisition of The New Zealand King Salmon Co Limited and is subject to annual impairment testing. The Group performs an annual impairment test in June each year. The Group considers the relationship between its market capitalisation and its book value, among other indicators, when reviewing for Indicators of impairment.

The goodwill is notionally allocated to the New Zealand King Salmon Company's operating segments as cash generating units. The recoverable amounts of the cash generating units have been determined based on a value in use calculation using future estimated cash flows, capital expenditure and changes in working capital over a five year period, plus an estimated terminal value. The forecasts were based on actual results and expected future use of water space licences currently held, before fair value adjustments to biological assets. The growth rate used to estimate the cash flows of the unit beyond the five-year period is 1.7% p.a. (2017: 3.3% p.a.). A discount rate of 10.36% p.a. (2017: 11.1% p.a.) has been applied to discount future estimated cash flows to their present value. The net present value of these future estimated cash flows exceeds the carrying amount of goodwill therefore the Company has concluded that there is no impairment to the goodwill.

The calculation of value in use is most sensitive to changes in sales prices, exchange rates, sales volumes and fish performance. Reasonably probable changes in the assumptions used would not cause the carrying value of goodwill to exceed the recoverable amount for any of the cash generating units.

Trade marks

Trademarks are externally acquired and are carried at cost less impairment. They have Indefinite useful lives and are assessed annually for impairment. No impairment has been recognised during the period (2017: Nil).

18. NON-CURRENT ASSETS HELD FOR SALE

The Mariborough Salmon Farm Relocations Advisory Panel report (made publicly available in February 2018) did not recommend the relocation of New Zealand King Salmon Crall Bay sites which were previously classified as Marine Licence Held for Sale. This has resulted in the reintroduction of these licences to intangibles. In accordance with NZ IFRS 5 this has been at the amortised value that would have been recognised if the asset had not been held for sale, \$308K (FY17: \$421K). The difference has been recognised as an Expense in the Statement of Comprehensive Income.

FOR THE YEAR ENDED 30 JUNE 2018

19. INTEREST BEARING LOANS AND BORROWINGS	2018	2017
Current Interest bearing loans and borrowings	\$000	\$000
Finance lease liabilities	133	144
Secured bank loans	1300	-
Other borrowings	328	270
Total current interest bearing loans and borrowings	461	414
Non-current Interest bearing loans and borrowings		
Finance lease liabilities		124
Secured bank loans	10,000	10,000
Other borrowings -	the second secon	CONTRACTOR OF STREET
Total non-current Interest bearing loans and borrowings	10,000	10,124

The Company has facilities with BNZ for \$30m, secured by a general security deed over the assets of the Group. The expiry date of facility A of \$18m is 25 November 2020, and facility B of \$12m expires on 18 October 2019. At balance date \$10m of facility A was drawn (June 2017: \$10m).

20. TRADE AND OTHER PAYABLES	2018	2017
Trade and other payables	\$000	\$000
Trade payables	11,170	11,318
Other payables	2,754	1,964
Total trade and other payables	13,924	13,282
21. EMPLOYEE BENEFITS	2018	2017
Current employee benefits	\$000	\$000
Bonuses	1,193	903
Employee annual and sick leave benefits	2,022	1,956
Long service leave	169	169
Total current employee benefits	3,384	3,028
Non-current employee benefits		
Long service leave	473	451
Total non-current employee benefits	473	451

Long service leave

Long service leave provisions are calculated based on the expected future payments to employees, discounted to their net present value.

22. COMMITMENTS AND CONTINGENCIES

Operating leases
The Group has entered into various operating lease arrangements with providers of premises, vehicles, water space and equipment. Many of these arrangements are for specified terms with rights of renewal on expiry of the terms. The commitments under non-cancellable operating leases take into account the renewal periods existing at balance date and are as follows:

	2018	2017
Operating lease commitments as a lessee	\$000	\$000
Less than one year	568	607
Between one and five years	1,052	948
More than five years		722
Total operating lease commitments as a lessee	1,620	2,277

Finance leases

The Group has finance leases for various items of plant and machinery. The Group's obligations under finance leases are secured by the lessor's title to the leased assets. Future minimum lease payments under finance leases, together with the present value of the net minimum lease payments are as follows:

	Minimum lease payments	Present value of payments
Finance lease commitments as at 30 June 2018	\$000	\$000
Less than one year	133	133
Between one and five years		_
Total finance lease commitments as at 30 June 2018	133	133
Finance lease commitments as at 30 June 2017		
Less than one year	143	125
Between one and five years	124	108
Total finance lease commitments as at 30 June 2017	267	233

The Group has entered into agreements to purchase plant and equipment. As at 30 June 2018 the total commitment is \$1,547k (2017: \$1,137k).

Contingencies
The Group has a contingent liability of \$1,066k in respect of a fish transport contract requiring the Group to purchase three bulk tankers (including modifications made in 2018), should the fish transport contract be terminated early. (2017; \$995k).

Guarantees

The group has three guarentee facilities totalling \$115k

FOR THE YEAR ENDED 30 JUNE 2018

23. FINANCIAL RISK MANAGEMENT

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group uses derivative financial instruments to hedge certain risk exposures. Financial risk management is the responsibility of the Chief Financial Officer in accordance with the Treasury Policy approved by the Board of Directors. In addition, the Group has a Treasury Committee, a sub-committee of the Board that oversees financial risk management.

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. This comprises of two key types of risks; currency and interest rate risk.

Currency rick

The Group has exposure to foreign exchange risk as a result of transactions denominated in foreign currency, arising primarily from normal trading activities, but also from the net investment in the foreign subsidiary.

The Group manages its foreign currency risk by hedging its future exposure in respect of its import purchases and its export sales, over a maximum of five years, when exposures are considered highly probable. The Group hedges this exposure with the use of forward foreign exchange contracts and options. The notional contract mounts of forward foreign exchange contracts and options outstanding at balance date were \$47.5m on the import side (2017: \$57.6m) and \$126.2m on the export side (2017: \$79.3m), for delivery over the next five financial years, in line with anticipated payment dates.

The Group Imports feed from Chile and Australia, purchases of which are in US and Australian dollars respectively. In order to protect against exchange rate movements and to manage the inventory costing process, the Group has entered into forward exchange contracts to purchase Australian, United States dollars and Japanese yen.

The Group exports salmon to many countries, the major ones being Australia, Japan and the United States. Sales are denominated in Australian dollars, Japanese yen and US dollars respectively. The Group has entered into forward exchange contracts to sell Yen and US dollars.

The cash flows are expected to occur up to 60 months from 1 July 2018. The profit and loss within cost of sales will be affected as sales are made.

The Group tests each of the designated cash flow hedges for effectiveness on a monthly basis both retrospectively and prospectively using the ratio offset method. If the testing falls within the 80%:125% range, the hedge is considered highly effective and continues to be designated as a cash flow hedge. At balance date all foreign currency hedges were determined to be highly effective.

The NZ dollar equivalent of unhedged currency risk on assets at balance date is \$113k (2017: \$220k) whilst the NZ dollar equivalent of unhedged currency risk on liabilities at balance date is \$31k (2017: \$86k).

Currency sensitivity

The following table demonstrates the sensitivity to a reasonably possible change in the value of the New Zealand Dollar against the key currencies to which the Group is exposed. The impact on the Group's pre-tax profit is the result of a change in fair value of monetary assets and liabilities. The impact on the Group's equity is due to changes in the fair value of forward exchange contracts and options designated as cash flow hedges.

As at 30 June 2018	Equity \$000	Profit \$000
Impact of a 5% strengthening of the NZD	2,027	(264)
Impact of a 5% weakening of the NZD	(2,199)	292
Impact of a 10% strengthening of the NZD	3,924	(505)
Impact of a 10% weakening of the NZD	(4,653)	617
As at 30 June 2017		
Impact of a 5% strengthening of the NZD	94	(32)
Impact of a 5% weakening of the NZD	(151)	29
Impact of a 10% strengthening of the NZD	150	(68)
Impact of a 10% weakening of the NZD	(346)	56

Interest rate risk

The Group has exposure to interest rate risk that arises mainly due to the Group's long term debt obligations with floating interest rates. Interest earned on call deposits are based on the current interest rate. Interest rate swaps are used to manage interest rate risk, current swap cover out to 2024. The amount of Parent borrowing covered using swaps at balance date was \$10m (2017: \$10m).

The Group manages its interest rate risk by hedging its future exposure with interest swaps, fixing a minimum of 50% of a rolling 12 month projected debt balance. Longer dated periods may be covered with forward starting swaps out to a maximum of 10 years.

Interest rate swaps in place at balance date cover 100% (2017: 100%) of the principal outstanding and are timed to expire in the next three to forty-two months. Forward starting swaps have been used to further extend maturities out to 2024 (\$10m). The fixed Interest rates for the existing swaps range between 4.3% and 5.01% (2017: 3.4% and 4.75%) and the floating rate of 2.03% is aligned to the floating quarterly bank bill rate. The loss on interest rate swaps at balance date was \$1,142k (2017: \$986k loss), which has been taken to reserves.

FOR THE YEAR ENDED 30 JUNE 2018

Interest rate sensitivity

The following table demonstrates the sensitivity of the fair value of the interest rate swaps to a reasonably possible change in interest rates:

	2018	2017
	\$000	\$000
Impact of an increase of 50 basis points	287	319
Impact of a decrease of 50 basis points	(298)	(334)

Credit risk

Credit risk is the risk of financial loss that arises if a counterparty to a financial instrument does not meet its contractual obligations. Financial instruments which potentially subject the Group to credit risk principally consist of bank balances, trade receivables, derivative financial instruments and financial guarantees.

Financial instruments are only entered into with banks that have in place an executed international Swaps and Derivatives Association (ISDA) Master Agreement with the Group.

Maximum exposures to credit risk as at balance date are:	2018	2017
5.1	\$000	\$000
Cash and short term deposits	14,428	10,647
Trade and other receivables	12,426	11,688
Derivative financial assets/(ilabilities)	88	45

The above maximum exposures are net of any recognised provision for losses. No collateral is held on the above amounts.

Concentrations of credit risk

Bank balances are maintained with several banks but mainly with Bank of New Zealand. There is a wide spread of debtors, in terms of size and geographical location within New Zealand and overseas. Concentration of credit risk in trade receivables is not considered significant as the Group's customers operate in different market channels and geographic areas.

Liquidity risk

The Group performs cash flow forecasting activities on a daily basis to ensure it has sufficient cash to meet operational needs and monitors performance against bank covenants on a monthly basis. Surplus cash is invested in short-term or money market deposits.

Undrawn committed facilities and/or liquid assets are maintained at all times at an amount sufficient to cover the forecast cash payments to employees, suppliers, tax authorities and banking institutions as they fall due.

The following table analyses the contractual and expected cash flows for all financial liabilities:

		Less than one year	Between one and two years	Between two and five years
As at 30 June 2018		\$000	\$000	\$000
Bank loans		(4,580)	431	1,392
Finance lease liabilities		143	301	1,052
Trade and other payables	₩ ij	13,924	_	-
Financial guarantee contracts		115		
Total non-derivative liabilities		9,602	431	1,392
Forward foreign currency exchange contracts		42,518	47.088	25,788
Forward foreign currency options		21,931	17,639	15,771
Interest swaps		616	804	2,620
Total derivative liabilities		65,065	65,531	44,179
As at 30 June 2017	59			
Bank loans		330	371	1,351
Finance lease liabilities		144	80	44
Trade and other payables		13,282	-	
Financial guarantee contracts		315	315	315
Total non-derivative liabilities		14,071	766	1,710
Forward foreign currency exchange contracts		46,198	34,221	21,171
Forward foreign currency options		5,495	6,620	4,963
Interest swaps		252	245	603
Total derivative liabilities		51,945	41,086	26,737

FOR THE YEAR ENDED 30 JUNE 2018

24. FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying value of cash and short term deposits, trade receivables, trade payables and other current liabilities is considered a reasonable approximation to their fair value due to the short term maturities of these instruments.

The carrying value of the BNZ loan drawing of \$10m is considered a reasonable approximation of its fair value due to the short term maturities of the drawings. New Zealand King Salmon Investments has the discretion to roll these short term drawings out to 2020.

The following financial instruments of the Group are carried at fair value:

The fellowing interior meaduriers of the Group are carried at fair value.		
	2018	2017
Current derivative financial assets	\$000	\$000
Forward exchange contracts	662	1,776
Foreign exchange options	395	290
Total Current derivative financial assets	1,057	2,066
Non-current derivative financial assets		
Forward exchange contracts	892	1,882
Foreign exchange options	992	1,314
Total Non-current derivative financial assets	1,884	3,196
Current derivative financial liabilities		
Forward exchange contracts	213	519
Foreign exchange options	150	24
Interest rate swaps	826	734
Total Current derivative financial liabilities	1,189	1,277
Non-current derivative financial liabilities		
Forward exchange contracts	425	451
Foreign exchange options	630	307
Interest rate swaps	244	190
Total non-current derivative financial liabilities	1,299	948

The carrying value of obligations under financial leases differs from fair value as follows:

	As at 30 Jun	As at 30 June 2018		e 2017
	Carrying amount	Fair value	Carrying amount	Fair value
	\$000	\$000	\$000	\$000
Obligations under finance leases	133	133	267	233
Total obligations under finance leases	133	133	267	233

Valuation methods

Financial instruments have been categorised into the following hierarchy and valued according to the following definitions, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date
Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from

Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs)

All derivative financial instruments for which a fair value is recognised have been categorised within level 2 of the fair value hierarchy. Industry experts have provided the fair values for all derivatives based on an industry standard model.

25. CAPITAL MANAGEMENT

Group capital

The capital of the Group consists of share capital, reserves and retained earnings. The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders, benefits for shareholders and to maintain an optimal capital structure to reduce the cost of

In addition to this the Group aims to ensure that it meets financial covenants attached to the interest bearing loans and borrowings that define capital structure

requirements. There have been no breaches in the financial covenants of any interest-bearing loans and borrowings in the current period.

In order to maintain or adjust the capital structure the Group may adjust dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

FOR THE YEAR ENDED 30 JUNE 2018

26. CAPITAL AND RESERVES

Share capital	2018	2017
Issued shares	000	000
Ordinary shares	138,475	138,158
Total issued shares	138,475	138,158

Ordinary shares are fully paid with no par value. Each ordinary share has an equal right to vote, to participate in dividends, and to share in any surplus on winding up of the Company. Dividends paid during the year consisted of a fully imputed dividend of \$0.02 per share and a \$0.01 per share special dividend both paid on 6 September 2017. Additionally, a fully imputed interim dividend of \$0.02 per share was paid on 14 March 2018 (2017: \$0.02 paid on 24 March).

	# of Shares		Share Capital	
PLANCE AND DESCRIPTION OF SELECT OFFICE AND ADDRESS OF SELECT AND	2018	2017	2018	2017
Movement in ordinary share capital	000	000	\$000	\$000
As at 1 July	138,158	25,295	122,518	25,296
Shareholder loans converted to share capital	10 sep	26,941		70,202
Shares issued by way of 2.11 to 1 share split	: 	57,955		-
Issue of new shares pursuant to IPO		26,786		30,000
Transactional costs arising on share Issue		-		(1,797)
Employee offer pursuant to IPO LTI share ownership plan	. - .	1,181		1,322
Share issue for employee LTI share scheme	317	* *******		(2,505)
Share issue recognised on repayment of employee loans	and the same and the same and		61	
Total share capital as at 30 June	138,475	138,158	122,579	122,518

Foreign currency translation reserve

The foreign currency translation reserve is used to record exchange difference arising from the translation of the financial statements of the foreign subsidiary.

Hedge reserve
The hedge reserve represents the unrealised gains and losses on interest rate swaps and foreign currency forward contracts that the Group has taken out in order to mitigate interest rate and foreign currency risks, net of deferred tax.

Share based payment reserve

The share based payment reserve relates to two long term incentive (LTI) schemes and and two employee share ownership scheme. All of these schemes involve the Company making interest-free limited recourse loans to selected personnel to acquire shares in the Company. The employees must remain in employment for the duration of the vesting or escrow periods before the employees receive the full benefit of share ownership.

The senior leadership share ownership plan LTI scheme was established prior to the IPO and relates to 3,176,878 shares in the Company. The ordinary shares in the Company are security for the interest-free limited recourse loans and are held in escrow until after the financial results have been announced for the year ending 30 June 2018.

The senior executive LTI scheme was established at the time of the IPO and relates to 993,671 shares in the Company. The ordinary shares in the Company are security for the interest-free limited recourse loans, are held by a Custodian and will vest three years from the granting date of 19 October 2016. The price to be paid for each share is the issue price at grant date, reduced by any dividends that are applied to the interest-free limited recourse loans. No shares vested, expired during the year, however 202,714 shares were forfeited during the year.

A further 317,515 shares were issued on 29 September 2017 with vesting date being 1 September 2020. These shares are also held by a Custodian with the ordinary shares in the Company being security for the interest free limited recourse loan. The price to be paid for each share is the issue price at grant date, reduced by any dividends that are applied to the interest free limited recourse loan. No shares vested or expired during the year however 13,024 shares were forfeited during the year.

The employee share ownership scheme was established at the time of the IPO and relates to 187,076 shares in the Company and was established at the time of the IPO. The ordinary shares in the Company are security for the interest-free limited recourse loans which may remain in place whilst the holder is in employment with the Company.

The estimated value of share options was determined using the Black-Scholes pricing calculator and is being amortised over the respective restrictive periods. The option cost is treated as an employee expense with the corresponding credit included in the share based payment reserve. The inputs into the option pricing valuation model are the acquisition or granting date, initial issue at the time of the IPO in October 2016, share price of \$1.12, and \$1.22 for further shares issued in September 2017 or \$1.77 for those who joined the scheme in September 2017 (which accordingly is the option exercise price), expected share price volatility of 14.1%, option life relative to each respective vesting or escrow period and a risk free interest rate of 2.1%. During the year 215,738 forfelted LTI shares were held by the Company as treasury stock, and may be issued to nominated executives in future grants of LTI shares.

Retained earnings

Retained earnings represents the profits retained in the business.

27. EVENTS AFTER BALANCE DATE

2018	2017
\$000	\$000
4,152	2,763
	1,382
4,152	4,145
	4,152

A final fully imputed dividend of 3 cents per share on ordinary shares was approved on 28 August 2018 for payment on 21 September 2018. These dividends are not recognised as a liability as at 30 June 2018.

FOR THE YEAR ENDED 30 JUNE 2018

28. RELATED PARTY DISCLOSURES

Subsidiaries

New Zealand King Salmon Investments Limited has the following trading subsidiaries.

Subsidiary	Company of Incorporation	Equity Interest
The New Zealand King Salmon Co Limited	New Zealand	100%
New Zealand King Salmon Exports Limited	New Zealand	100%
The New Zealand King Salmon Pty Limited	Australia	100%
New Zealand King Salmon USA Incorporated	United States of America	100%

The principal activity of The New Zealand King Salmon Co Ltd is the farming and processing of salmon. The activity of New Zealand King Salmon Exports Ltd, The New Zealand King Salmon Pty Ltd, and New Zealand King Salmon USA Inc is the distribution of salmon.

At balance date Oregon Group Limited owned 40.16% (30 June 2017: 40.26%) and China Resources Ng Fung Limited owned 9.97% (30 June 2017: 9.97%) of the shares in New Zealand King Salmon Investments Limited.

Transactions with related parties
Sales to and purchases from related parties are made in arm's length transactions both at normal market prices and on normal commercial terms. The following provides the total amount of transactions that were entered into with related parties for the relevant financial year:

Related party payments	2018 \$000	2017
Interest paid - Oregon Group Limited		272
Interest paid - Other shareholders	%E:	194
Good and services purchased from other related parties	63	258
Total related party payments	63	724
Related party sales	SANCTATION DESCRIPTION OF STREET	
Goods and services sold to related parties	(1,527)	(462)
Total related party sales	(1,527)	(462)
Sales to and purchases from related parties are made in arm's length transactions, both at norm	al market prices and on normal commercial terms.	
Amounts owing to related parties	2018	2017
Current amounts owing to related parties	\$000	\$000
Other amounts owing to related parties	46	18
Total current amounts owing to related parties	46	18
Non-current amounts owing to related parties		
	2018	2017
Amounts owing by related parties	\$000	\$000
Amounts owing by related parties	177	94
Total amounts owing by related parties	177	94
Compensation of key management personnel of the Group	2018	2017
Key management personnel compensation	\$000	\$000
Short-term employee benefits	1,947	2,159
		112
Share based payment expense	161	112
Share based payment expense Post employment pension and medical benefits	161 86	108

FOR THE YEAR ENDED 30 JUNE 2018

29. AUDITORS REMUNERATION		2018	2017
Auditors remuneration		\$000	\$000
Audit fees	9	112	95
Other assurance		33	45
Tax compliance and consultancy		67	88
Taxation advisory services			175
Total auditors remuneration	100 S	212	403

Other assurance services include review of the Interim financial statements and performance of agreed upon proceedures on sustainability information of the Group. The prior year, also included transactional advisory services relating to work performed as investigative accountants in connection with the public offer of shares in the

30. RECONCILIATION OF NET OPERATING CASH FLOW TO PROFIT/(LOSS) 2018 Reconciliation of the profit for the year with the net cash from operating activities \$000 700
Reconcilitation of the profit for the year with the net cash from operating activities \$000 Profit before tax \$2,687 \$32 Adjusted for \$1,000 Depreciation and amortisation \$5,105 \$4, (Gain)/loss on sale of assets \$94 Loss on Asset Held for Sale \$2 Share-based payments \$263 Net foreign exchange differences \$367 Capitalised interest on shareholder loans \$4611 \$(\$6,562) \$(\$9,\$) (Increase) in terest on shareholder loans \$(\$461) \$(\$1,000 Income tax expense \$(\$6,562) \$(\$9,\$) (Increase) in deferred tax on reserves \$(\$6,562) \$(\$9,\$) (Increase) in terest and other receivables and prepayments \$(\$6,562) \$(\$9,\$) (Increase) in tax each and other payables \$1,000 \$(\$1,\$) (Increase) in tax each and other payables \$1,000 \$(\$1,\$) (Increase) in tax each flow from operating activities \$2,186 \$8, Net cash flow from operating activities \$24,838 \$5, \$1,000 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS \$2018 Cost of goods sold \$1,000 \$1,000 \$1,000 Fair value gain on biological transformation \$50,309 \$37, \$000 Solution of the profit of the payable of the payable of the payable on biological transformation \$50,309 \$37, \$1,000 Cost of goods sold \$1,000 \$1,000 Fair value gain on biological transformation \$50,309 \$37, \$1,000 Cost of goods sold \$1,000 \$1,000 Cost of goods sold \$1,000 C
Profit before tax 22,687 32 Adjusted for Depreciation and amortisation 5,105 4, (Gain)/loss on sale of assets 94 4, Loss on Asset Held for Sale 2 Share-based payments 263 Net foreign exchange differences 367 Capitalised interest on shareholder loans - Kovement in prepaid insurances and other loans (461) (562) (9, Increase) in deferred tax on reserves 721 (1,
Adjusted for Depreciation and amortisation 5,105 4 (Galn)/loss on sale of assets 94 4 Loss on Asset Held for Sale 2 5hare-based payments 263 Net foreign exchange differences 367 - Capitalised interest on shareholder loans - - Movement in prepaid insurances and other loans (481) (Income tax expense (6,562) (9, (Increase) Inderred tax on reserves 721 (1, (Increase) Inderred tax on reserves (738) (1, (Increase)/decrease in Inventories and biological assets (738) (1, (Increase)/decrease in Inventories and other payables 1,020 (1, Increase/(decrease) in trade and other payables 1,020 (1, Increase/(decrease) in trade and other payables 2,186 8 Net cash flow from operating activities 24,838 5 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS Actual Prospective Prospective Prospective Financial Statements Prospective Prospective Financial Statements 160,271 143,200 142,200 1422,200 </td
(Gain)/loss on sale of assets 94 Loss on Asset Held for Sale 2 Share-based payments 263 Net foreign exchange differences 367 Capitalised interest on shareholder loans - Movement in prepaid insurances and other loans (461) (Income tax expense (6,562) (9, (Increase) In deferred tax on reserves 721 (1, (Increase)/decrease in trade and other receivables and prepayments (738) (1, (Increase)/decrease in inventories and biological assets 154 (25, Increase//decrease) in trade and other payables 1,020 (1, Increase//decrease) in tax liabilities 2,186 8, Net cash flow from operating activities 24,838 5 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS Actual Prospetation Prospetation a. Revenue 160,271 143, Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
(Galn)/loss on sale of assets 94 Loss on Asset Held for Sale 2 Share-based payments 263 Net foreign exchange differences 367 Capitalised interest on shareholder loans - Movement in prepaid insurances and other loans (461) (Income tax expense (6,562) (9, (Increase) in deferred tax on reserves 721 (1, (Increase)/decrease in trade and other receivables and prepayments (738) (1, (Increase)/decrease in inventories and biological assets 154 (25, Increase//decrease) in trade and other payables 1,020 (1, Increase//decrease) in tax liabilities 2,186 8, Net cash flow from operating activities 24,838 5 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS Actual Prospetation Prospetation a. Revenue 160,271 143, Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
Loss on Asset Held for Sale 2 5 5 5 5 5 5 5 5 5
Net foreign exchange differences 367 Capitalised Interest on shareholder loans - Movement In prepaid Insurances and other loans (481) (1850) Income tax expense (6,562) (9,90) (Increase) In deferred tax on reserves 721 (1,180) (Increase) In trade and other receivables and prepayments (738) (1,180) (Increase)/decrease in inventories and biological assets 154 (25,180) Increase//decrease) In trade and other payables 1,020 (1,180) Increase//decrease) In tax liabilities 2,186 8,800 Net cash flow from operating activities 24,838 5,500 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS Actual Prospection 4,000 a. Revenue 160,271 143, 143, 143, 144, 144, 144, 144, 144,
Net foreign exchange differences 367 Capitalised Interest on shareholder loans - Movement In prepaid Insurances and other loans (481) (1850) Income tax expense (6,562) (3,90) (Increase) in deferred tax on reserves 721 (1,180) (Increase) in trade and other receivables and prepayments (738) (1,180) (Increase)/decrease in inventories and biological assets 154 (25,180) Increase//decrease) in trade and other payables 1,020 (1,180) Increase//decrease) in tax liabilities 2,186 8,800 Net cash flow from operating activities 24,838 5,500 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS Actual Prospection 4,000 a. Revenue 160,271 143, 143, 143, 144, 144, 144, 144, 144,
Capitalised Interest on shareholder loans (461) (161)
Movement in prepaid insurances and other loans (461) (16,562) (9,16,562) (9,16,562) (16
Income tax expense (6,562) (9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10
(Increase) In deferred tax on reserves 721 (1, (1, (1), (1), (1), (1), (1), (1), (1
(Increase)/decrease in trade and other receivables and prepayments (738) (1, (1, crease)/decrease in inventories and biological assets 154 (25, (25, (25, (25, (25, (25, (25, (25,
(Increase)/decrease in inventories and biological assets 154 (25, Increase)/(decrease) in trade and other payables 1,020 (1, Increase)/(decrease) in trade and other payables 1,020 (1, Increase)/(decrease) in trade and other payables 2,186 8, Net cash flow from operating activities 24,838 5, 31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS Actual Prospective Prospec
Increase (decrease) in trade and other payables 1,020 (1,100 1,000
Increase (decrease) in tax liabilities
Net cash flow from operating activities 24,838 5
31. COMPARISON TO PROSPECTIVE FINANCIAL STATEMENTS 2018 2018 5000 a. Revenue Cost of goods sold Fair value gain on biological transformation 50,309 37.
a. Revenue 2018 \$000 160,271 143, Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
a. Revenue 160,271 143, Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
a. Revenue 160,271 143, Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
Cost of goods sold (145,320) (122, Fair value gain on biological transformation 50,309 37,
Fair value gain on biological transformation 50,309 37,
Gross profit 50,048 44,
Other operating income 1,822
Sales, marketing and advertising expenses (10,381) (9,
Distribution overheads (3,348) (2,
Corporate Expenses (6,728) (7,78)
Other expenses (2,931)
Collect expenses (2,5317) Earnings before interest, tax, depreciation and amortisation 28,482 26,
Zamings before interest, tax, depreciation and amortisation 20,402 20,
Depreciation and amortisation (5,105) (5,105)
Finance Income 198
Finance expenses (888)
Profit before tax 22,667 19
Income tax expense (6,562) (5,
Net profit after tax 16,125 14

Explanation of variances

The fair value gain on biological transformation is higher than the prospective financial information (PFI) due to increases in sales price and average weight at harvest (see note 15). Gross profit is also higher than PFI due to higher sales volumes and price increases. Other operating income primarily relates to a supplier feed rebate included under cost of goods sold in PFI.

FOR THE YEAR ENDED 30 JUNE 2018

b.	Prospective statement of financial position	2 V: 2	
	ASSETS	Actual 2018	Prospective 2018
	Current assets	\$000	\$000
	Cash and cash equivalents	14,428	647
	Trade and other receivables		
	Irade and other receivables	12,426	12,499
		16,582	19,575
	Biological assets	71,568	64,974
	Assets held for sale		421
	Other financial assets	4 007	1,475
	Derivative financial assets	1,057	96
	Total current assets	116,059	99,687
	Non-current assets	1900 EREST.	
	Property, plant and equipment	43,722	44,449
	Biological assets	7,888	11,162
	Derivative financial assets	1,884	(A)
	Deferred tax asset	2,052	1,343
	Intangible assets	5,114	2,954
	Goodwill	39,255	39,255
	Total non-current assets	99,915	99,163
	TOTAL ASSETS	215,974	198,850
	LIABILITIES		
	Current liabilities		
	Trade and other payables	13,924	20,460
	Employee benefits	3,384	2,433
	Borrowings	461	178
	Other financial liabilities	46	72
	Derivative financial liabilities	1,189	992
	Taxation payable	4,902	580
	Total current liabilities	23,906	24,643
	Non-current liabilities		
	Employee benefits	473	465
	Borrowings	10,000	10,089
	Deferred tax liabilities	13,995	9,899
	Derivative financial liabilities	1,299	-
	Total non-current liabilities	25,767	20,453
	TOTAL LIABILITIES	49,673	45,096
	NET ASSETS	166,301	153,754
	EQUITY		
	Share capital	122,579	123,334
	Reserves	328	(493)
	Retained earnings	43,394	30,913
			153,754
	CONTRACTOR		1,00,1,04
	TOTAL EQUITY	166,301	

Explanation of variances

Cash and cash equivalents are up on PFI due to the higher profit during the PFI period, as inventories being lower that forecasted in PFI and also due to timing of tax payments. This coupled with an increase in the value of biological assets (due to increases in gross margin and average size at balance sheet date) have led to a significant increase in net assets. Trade and other payables are lower than PFI due to timing of capital expenditure, feed purchases and other creditor payments. Deferred tax liabilities were greater than PFI as a result of a combination of these same factors.

FOR THE YEAR ENDED 30 JUNE 2018

c. Prospective statement of changes in equity	Actual	Prospective
	2018	2018
	\$000	\$000
Balance at beginning of period	158,675	144,617
Issue of shares	61	1.5
Change in other reserves .	(1,467)	288
Total profit for the period	16,125	14,149
Dividends paid	(7,093)	(5,300)
Balance at End of Year	166,301	153,754
Equity breakdown by component		
Share capital	122,579	123,334
Reserves	328	(493)
Retained earnings	43,394	30,913
Total equity	166,301	153,754
Explanation of variances		
	ofit during the PFI period and the movements in cash flow hedge reserve as a result of changes in fo	orward currency
contract positions and movements in foreign exchar	ige rates.	
d. Prospective statement of cash flows	Actual	Prospective
a. Trospective statement of cash nows	2018	2018
Operating Activities	5000	\$000
Receipts from customers	161,212	142,534
Payments to suppliers and employees	(132,482)	(125,966)
Interest received	164	
Interest paid	(597)	(478)
Feed supplier settlement	150	•
Income tax paid	(3,609)	(4,567)
Net cash flows from operating activities	24,838	11,523
Investing Activities		
Proceeds from sale of property, plant and equipmer	nt 19	(4)
Purchase of property, plant and equipment	(14,022)	(11,065)
Purchase of intangible assets	(88)	N 71 💆
Net cash flow from investing activities	(14,091)	(11,065)
Financing Activities		
Drawdown of revolving loan	124	
Government grants received	148	- 2
Gross proceeds from share issue	42	- I
Transaction costs arising from share issue	42	-
Proceeds from shareholder advances		
Repayment of shareholder advances	(89)	12
Payment of finance lease liabilities	(98)	Laure Co
Payment of dividends	(7,093)	(5,300)
Not cash flows from financing activities	(6,966)	(5,300)
Net Increase/(decrease) in cash and cash equiva	3,781 3,781	(4,842)
Cash and cash equivalents at 1 July	10,647	5,489
Cash and cash equivalents at 30 June	14,428	647

Explanation of variances

Receipts from customers are up as a result of increases in harvest value and average sales price vs PFI. Purchases of property, plant and equipment are up on PFI due to timing of capital projects. Payment of dividends are up due to the PY17 1.0cent per share special dividend as paid 18 September 2017.



Independent auditor's report to the Shareholders of New Zealand King Salmon Investments Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of New Zealand King Salmon Investments Limited ("the company") and its subsidiaries (together "the group") on pages 2 to 25, which comprise the consolidated statement of financial position of the group as at 30 June 2018, and the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended of the group, and the notes to the consolidated financial statements including a summary of significant accounting policies.

In our opinion, the consolidated financial statements on pages 2 to 25 present fairly, in all material respects, the consolidated financial position of the group as at 30 June 2018 and its consolidated financial performance and cash flows for the year then ended in accordance with New Zealand equivalents to International Financial Reporting Standards and International Financial Reporting Standards.

This report is made solely to the company's shareholders, as a body. Our audit has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's shareholders, as a body, for our audit work, for this report, or for the opinions we have formed.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (New Zealand). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report.

We are independent of the group in accordance with Professional and Ethical Standard 1 (revised) Code of Ethics for Assurance Practitioners issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Ernst & Young provides taxation services to the company and have performed other assurance services including review of the interim financial statements and performance of agreed upon procedures on sustainability information of the group. Partners and employees of our firm may deal with the group on normal terms within the ordinary course of trading activities of the business of the group. We have no other relationship with, or interest in, the group.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current year. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, but we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.



We have fulfilled the responsibilities described in the *Auditor's responsibilities for the audit of the financial statements* section of the audit report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements.

Valuation and existence of biological assets

Why significant

At 30 June 2018, the consolidated statement of financial position includes biological assets (live salmon) of \$79.5 million with a biomass of 5,391 metric tonnes measured at fair value less costs to sell. This includes a fair value increase above cost of \$36.8 million in the carrying amount.

This is a key audit matter because the company's estimation of the fair value of biological assets involves estimation of year end biomass, and a valuation model that relies on significant estimation including:

- period end and future biomass growth to harvest;
- future fish mortalities;
- forecast sales prices;
- costs to harvest date and sale;
- sales product mix; and
- weight based recognition of the present value of gross margin

The company's disclosures are included in Note 15 to the group financial statements.

How our audit addressed the key audit matter

Our approach to live salmon valuation focused on the following procedures. We:

- evaluated the appropriateness of key estimations and assumptions and their impact on discounted future cash flows;
- tested the mathematical accuracy of discounted cash flow forecasts;
- agreed key estimation inputs used by the company in their model to source data and to board approved budgets;
- involved our valuation specialists in the evaluation and testing of the mathematical logic and accuracy of the calculation in the valuation model and of the discount rate used; and
- challenged the accuracy of model inputs compared to historical actual values and considering the accuracy of previous input forecasts.

Our approach to live salmon existence focused on the following procedures. We:

- agreed a sample of the records of fish transfers to seafarms;
- considered the key inputs used by the company in estimating growth and biomass;
- tested controls over fish quantity and biomass adjustments to the livestock recording system;
- agreed significant quantity and biomass adjustments made by the company in the livestock recording system to source data;
- performed analytical procedures over feed conversion to biomass;
- considered the accuracy of previous internal forecasts of average fish weight, and quantity of fish harvested compared to the livestock recording system; and



 considered the appropriateness, sufficiency, and clarity of biological assets disclosures included in the group financial statements.

Goodwill impairment assessment

Why significant

At 30 June 2018, the consolidated statement of financial position includes goodwill acquired in business combinations of \$39.3 million, assigned to three cash generating units (CGUs).

This is a key audit matter because the annual impairment assessment of goodwill involves significant judgements related to future cash flow forecasts, discount rate and terminal growth rate assumptions.

The company's disclosures are included in Note 17 to the group financial statements.

How our audit addressed the key audit matter

Our approach focused on the following procedures. We:

- evaluated the basis of the group's CGU determination;
- assessed the allocation of goodwill to CGUs;
- evaluated the appropriateness of key assumptions and their impact on estimated future cash flows;
- tested the mathematical accuracy of future cash flow forecasts;
- involved our valuation specialists in assessing the discount rate and terminal growth rate applied;
- agreed inputs used by the company in their model to assess impairment, to board approved budgets, and compared these with historical actual results. We also considered the accuracy of previous internal forecasts;
- performed sensitivity analyses on key future cash flow forecast assumptions, including earnings before interest, tax, depreciation and amortisation; weighted average cost of capital and capital expenditure levels, to understand the impact of reasonably possible changes in key assumptions;
- compared the calculated recoverable values to the associated carrying amounts, and assessed whether any impairment charges were required; and
- considered the appropriateness, sufficiency, and clarity of goodwill disclosures included in the group financial statements.



Valuation of sea farm related assets

Why significant

At 30 June 2018, the consolidated statement of financial position includes sea farm assets recorded within property, plant and equipment of \$24.0 million, and related marine licences and resource consents recorded within intangible assets of \$3.5 million.

This is a key audit matter because the annual assessment of remaining useful lives, amortisation periods and identification of indicators of impairment involves significant judgements related to future sea farm use, marine licence and resource consent renewal and environmental compliance.

The company's disclosures are included in Note 16 and Note 17 to the group financial statements.

How our audit addressed the key audit matter

Our approach focused on the following procedures. We:

- considered the company's assessment of compliance with resource consents relating to sea farms;
- evaluated the appropriateness of key assumptions used by the company in their assessment of indicators of impairment of property, plant and equipment;
- evaluated the appropriateness of key assumptions used by the company in their determination of remaining useful lives of significant sea farm assets; and
- considered the appropriateness, sufficiency, and clarity of property, plant and equipment and marine licence intangible assets disclosures included in the group financial statements.

Information other than the financial statements and auditor's report

The directors of the company are responsible for the Annual Report, which includes information other than the consolidated financial statements and auditor's report which is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and, if uncorrected, to take appropriate action to bring the matter to the attention of users for whom our auditor's report was prepared.



Directors' responsibilities for the financial statements

The directors are responsible, on behalf of the entity, for the preparation and fair presentation of the consolidated financial statements in accordance with New Zealand equivalents to International Financial Reporting Standards and International Financial Reporting Standards, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing on behalf of the entity the group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (New Zealand) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

A further description of the auditor's responsibilities for the audit of the financial statements is located at the External Reporting Board's website: https://www.xrb.govt.nz/standards-for-assurance-practitioners/auditors-responsibilities/audit-report-1/. This description forms part of our auditor's report.

The engagement partner on the audit resulting in this independent auditor's report is Bruce Loader.

Chartered Accountants

Christchurch

28 August 2018